1. Scrip
  2. >>Business

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

 
• By Mandy Jackson

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Finance Watch

Recent biopharmaceutical initial public offerings show that the IPO boom is not limited to the US, and illustrate the challenges of going public in any market.

US stock values have plummeted in recent weeks, including drug developer stocks, which should make it more difficult for some biopharma firms to go public. (Also see "Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public" - Scrip, 31 October, 2018.) Nevertheless, companies still are attempting to launch large offerings, including Moderna Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.